Ohio bill offers protection for off-label prescriptions
COLUMBUS, Ohio (WCMH) — A discussion about off-label drugs is back in the spotlight in Ohio after a similar effort failed last year.
House Bill 12 would generally allow a doctor to prescribe any drug, even if it is for off-label use, and require a pharmacist to dispense it. An off-label drug is when it is prescribed for a purpose that is not explicitly approved by the FDA.
May 2025 primary election results for central Ohio
'It stems from a lot of the criticisms we've heard surrounding COVID response,' Ohio Rep. DJ Swearingen (R-Huron), the bill's sponsor, said. 'Doctors who felt like they had an idea of how they wanted to handle that disease and wanted to go one way with it and were kind of outcasts in some sort of sense.'
Off-label drug prescriptions have been used in more cases than just COVID-19 and Ivermectin. Executive Director of the Ohio Pharmacist Association David Burke said it is most prevalent today, for example, in diabetes drugs, like Ozempic, being used for weight loss.
'Currently, today, off-label prescribing and dispensing occurs unencumbered,' Burke said.
Swearingen said that if an off-label prescription can work in the best interests of a patient, then physicians and prescribers should 'have the freedom to pursue that option.' He said there is little 'medical free speech' and this bill would protect that.
'So, if a doctor gives an opinion in a medical setting that they can do that without threat of retaliation from a regulatory board or a licensing board for something along those lines,' Swearingen said.
Black smoke rises from Sistine Chapel chimney, conclave doesn't elect pope in first vote
Burke argued that there is a different standard of free speech when it comes to medical professionals.
'Physicians don't have free speech for personal opinion on how drugs are to be used, they use scientific background just like pharmacists do or nurses do, and they administer care to a patient,' Burke said.
Burke said he worries that under this legislation, pharmacists will have little ground to push back when they think a prescription will be harmful to a patient. He said often, pharmacists have information about certain drugs before a prescriber might.
'This returns us to the days of Dr. Smith's medicine wagon, where he has a liquid that will cure your rheumatism,' Burke said. 'That's where we're going. That's who this empowers.'
Burke said while he believes most prescribers do act with care, he worries about places like medical spas and the prescriptions that come from those establishments.
'We've got folks writing prescriptions for any valid reason to which they think a patient could use without scientific background,' Burke said. 'That's going to cause a lot of harm to patients and bypasses the current system that just allows an individual opinion rather than a scientific opinion.'
Which school issues central Ohio voters approved in May 2025 election
Swearingen said the bill already has a liability portion, and does not leave the prescriber completely immune should the drug cause harm to the patient and not meet the standard of care. He said that at the heart of the bill is wanting 'medical providers to seek the truth.'
'Also have a dialogue about what they believe to be best practices and what they believe to be in the patient's best interest without threat of retaliation,' he said.
The bill had its third hearing on Wednesday afternoon, which featured opponent testimony. Fifty-eight people against the bill either submitted written testimony or appeared in person. During the bill's proponent testimony hearing, 42 people supported it.
The bill failed to pass the Ohio Statehouse last year, in a last-minute move, but Swearingen said he is hopeful it will get through this time.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
For the latest news, weather, sports, and streaming video, head to NBC4 WCMH-TV.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Insider
3 hours ago
- Business Insider
Argenx presents new Efgartigimod data at EULAR 2025
argenx (ARGX) SE 'announced the presentation of positive results from Phase 2 studies evaluating VYVGART in Sjogren's disease and idiopathic inflammatory myopathies at the European Congress of Rheumatology, EULAR 2025, from June 11 – 14 in Barcelona, Spain. argenx also announced that the FDA has granted efgartigimod Fast Track designation for the treatment of primary Sjogren's disease.' Confident Investing Starts Here: Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Yahoo
3 hours ago
- Yahoo
ClearPoint Neuro, Inc. (CLPT): A Bull Case Theory
We came across a bullish thesis on ClearPoint Neuro, Inc. (CLPT) on M.V. Cunha's Substack. In this article, we will summarize the bulls' thesis on CLPT. ClearPoint Neuro, Inc. (CLPT)'s share was trading at $13.93 as of 6th June. A medical doctor surrounded by advanced technology in the operating room. ClearPoint Neuro is transforming from a surgical tools provider into a critical platform company enabling the next generation of neurological treatments. In the first quarter of 2025, revenue grew 31 percent year-over-year to 8.5 million dollars, led by the rapid adoption of its SmartFrame operating room system, which increased 70 percent and allows hospitals to use ClearPoint technology in standard surgical settings. This expansion seeds a larger installed base and drives high-margin recurring revenue from disposable instruments. The biologics and drug delivery segment generated 4.7 million dollars in revenue, growing 9 percent year-over-year, and is supported by more than 60 active partnerships with gene and cell therapy developers. As these therapies move toward commercial use, ClearPoint's role as the enabling delivery infrastructure could become its most profitable revenue stream, with each procedure generating over 20,000 dollars in high-margin recurring revenue. Meanwhile, the company is intentionally moving away from capital equipment sales, which declined 63 percent, in favor of a subscription-based model that provides predictable recurring revenue. Operating cash burn fell 35 percent in 2024, with expenses rising 29 percent in the latest quarter due to targeted investments in preclinical services, therapy support, and device innovation. ClearPoint closed the quarter with 12.4 million dollars in cash and access to up to 105 million dollars in financing, providing sufficient capital to reach financial breakeven without near-term equity dilution. While risks around execution, partner dependency, and regulatory pacing remain, ClearPoint's embedded position across neurological therapy development offers investors a unique opportunity to benefit from a long-term transformation into the backbone of next-generation brain treatments. Previously, we highlighted a on ClearPoint Neuro from northeasternsvf in January 2025, which emphasized its unique position as the only FDA-cleared, MRI-guided neurosurgical platform enabling precise delivery of CNS gene and cell therapies. That thesis focused on the company's expanding biopharma partnerships, operating room penetration through SmartFrame OR, and its path to profitability via high-margin disposables. ClearPoint Neuro, Inc. (CLPT) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 21 hedge fund portfolios held CLPT at the end of the first quarter which was 13 in the previous quarter. While we acknowledge the risk and potential of CLPT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than CLPT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.

Epoch Times
5 hours ago
- Epoch Times
Mikie Sherrill, Jack Ciattarelli Win the Democratic and Republican Primaries for Governor of New Jersey
WASHINGTON—U.S. Rep. Mikie Sherrill (D-N.J.) and former State Assemblyman Jack Ciattarelli (R-Somerville) won the Democratic and Republican primary contests in the New Jersey gubernatorial election on June 10 and will advance to the general election. Ciattarelli easily beat out his Republican opponents, leading with 66.3 percent of the vote with 28 percent counted. The Associated Press called the race for him at 8:17 p.m. ET. Sherrill's race took slightly longer to call, being declared the winner at 8:39 p.m.